title: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
authors.affiliation: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Costa
authors.forename: Susumu
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Shuchi S
authors.initials: SS
authors.lastname: Pandya
authors.forename: Wee-Lee
authors.initials: WL
authors.lastname: Yeo
authors.forename: Zhongzhou
authors.initials: Z
authors.lastname: Shen
authors.forename: Weiwei
authors.initials: W
authors.lastname: Tan
authors.forename: Keith D
authors.initials: KD
authors.lastname: Wilner
mesh_terms: D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D002289:Carcinoma, Non-Small-Cell Lung / Q000134:cerebrospinal fluid*; D000077547:Crizotinib; D017809:Fatal Outcome; D006801:Humans; D008175:Lung Neoplasms / Q000134:cerebrospinal fluid*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000134:cerebrospinal fluid*; D011720:Pyrazoles / Q000134:cerebrospinal fluid*; D011725:Pyridines / Q000134:cerebrospinal fluid*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases